Pharmacological remodeling of the thrombus architecture

Blood Coagulation and Fibrinolysis

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Collet, J P ^a,b   Montalescot, G ^a   Soria, J ^b   Mishal, Z ^d   Soria, C ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRIN;

ANIMAL; BLOOD; HUMAN; METABOLISM; PATHOLOGY; REVIEW; THROMBOCYTE; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; FIBRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0033071301     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol 1946; 58: 207-212.
2. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985; 71: 699-708.
3. De Wood MA, Spores J, Notske R,. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897.
4. Mizuno SK, Miyamoto A, Arakawa K, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-291.
5. Gold HK, Garabedian H, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without plasminogen activators. Circulation 1997; 95: 1755-1759.
6. Muhlestein JB, Karagounis L, Treehan S, Anderson JL. 'Rescue' utilization of Abciximab for the dissolution of coronary thrombus developping as a complication of coronary syndromes. Circulation 1998; 30: 1729-1734.
7. Blombäck B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1997; 83: 1-75.
8. Weisel JWW, Cederom-Williams S. Fibrinogen and fibrin: characterization, processing and medical applications. 1997: 347-365.
9. Braaten JV, Gray J, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood 1994; 83: 982-993.
10. Braaten JV, Handt S, Jerome W, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet fibrin thrombus. Blood 1993; 81: 1290-1298.
11. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with acute myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-542.
12. Collet JP, Soria J, Mirshahi MC, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-2469.
13. Bergqvist D. Dextran. In: Verstraete VF, Topol EJ (editors): Cardiovascular Thrombosis: Thrombocardiology and Thromboembolism, Second Edition. Philadelphia: Lippincott Williams & Wilkins; 1998. pp. 235-250.
14. Matthiasseon S, Lindblad B, Mätzsch T, Holst J, Bergqvist D. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb Haemost 1994; 71: 363.
15. Matthiasseon S, Lindblad B, Mätzsch T, Molin J, Quarford P, Bergqvist D. Study of the interaction of dextran and enoxaparin on haemostasis in humans. Thromb Haemost 1994; 72: 722.
16. Bjornsson TD, Schneider D, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154-61.
17. Fatah K, Beving H, Albage A, Ivert T, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient. Eur Heart J 1996; 17: 1362-1366.
18. Williams S, Fatah K, Ivert T, Blombäck M. The effect of acetylsalycylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coag Fibrinol 1995; 6: 718-724.
19. Group ISIS2. Randomized trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 1287-1294.
20. Eisenberg PR, Sherman L, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529.
21. Owen J, Friedman KD, Grossmann BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue-type-plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620.
22. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. Chest 1995; 108: 401-423.
23. Mirshahi M, Soria J, Soria C, et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA induced thrombolysis. Blood 1989; 74: 1025-1034.
24. Weitz JI, Huboda M, Massel M, Maraganore J, Hirsh. Clot-bound thrombin is protected from inhibition by heparin-antithrobin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
25. Weitz JI, Leslie B, Huboda M. Thrombin binds to soluble degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-553.
26. Antiplatelet Trialist's Collaboration Study. Collaborative overview of randomised trials of antiplatelets therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
27. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
28. The EPILOG Investigators. Platelets glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularzation. N Engl J Med 1997; 336: 1689-1696.
29. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c 7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149-156.
30. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 1284-1291.
31. Garcia-Dorado D, Théroux P, Tornos P, et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995; 92: 1743-48.
32. Rooney MM, Parise L, Lord ST. Dissecting clot retraction and platelet aggregation. J Biol Chem 1996; 271: 8553-8555.